BPTH
Bio-Path Holdings Inc

18,205
Loading...
Loading...
News
all
press releases
Is This Penny Stock a Buy After a 180% Rally?
Bio-Path Holdings surged 180% on promising obesity drug results. Discover why this penny stock's pivot from cancer treatments and Nasdaq delisting challenges could matter for investors.
barchart.com·8mo ago
News Placeholder
More News
News Placeholder
Bio-Path Rockets To 4-Month High As Obesity Drug Shows Promise For Diabetes: Retail In Celebration Mode
The company said it has initiated animal studies to further confirm the drug’s efficacy, with plans to launch a first-in-human Phase 1 trial in 2025.
Stocktwits·9mo ago
News Placeholder
Why Bio-Path Stock Is Soaring
Bio-Path Holdings shares are trading higher Thursday after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to...
Benzinga·1y ago
News Placeholder
Bio-Path Holdings Provides 2024 Clinical and Operational Update
Clinical Advances Across Multiple Programs with Several MilestonesHOUSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its...
Globe Newswire·1y ago
News Placeholder
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 23
Dallas, Texas--(Newsfile Corp. - March 27, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q4 2023...
Newsfile Corp. - News Releases·1y ago
News Placeholder
Bio-Path Holdings Reports Full Year 2023 Financial Results
Conference Call to be Held Today at 8:30 A.M. ETHOUSTON, March 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize...
Globe Newswire·2y ago
News Placeholder
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
HOUSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a...
Globe Newswire·2y ago
News Placeholder
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on February 23, 2024HOUSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH) (the Company ), a...
Globe Newswire·2y ago
News Placeholder
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
Targeting Bcl-2 Protein Offers Potential Treatment for Patients Who Have Failed or Relapsed from Venetoclax-Based Frontline TherapyHOUSTON, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings...
Globe Newswire·2y ago

Latest BPTH News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.